Novel compound PS-101 exhibits selective inhibition in non-small-cell lung cancer cell by blocking the EGFR-driven antiapoptotic pathway
Authors:
- Le-Jing CaiLCLe-Jing Cai
- Yan-Fei WangYWYan-Fei Wang
- Yuan-Hua ZhouYZYuan-Hua Zhou
- Yun-Feng AnYAYun-Feng An
- Yan-Cheng LiuYLYan-Cheng Liu
- Yan PengYPYan Peng
- Zhen-Feng ChenZCZhen-Feng Chen
- Hong LiangHLHong Liang
- 1 December 2013
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 86 (12) , 1721-1730
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivoInternational Journal of Cancer, 2012
- Inhibition of Basal FGF Receptor Signaling by Dimeric Grb2Cell, 2012
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialThe Lancet Oncology, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor PathwayClinical Lung Cancer, 2009
- Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancerAnnals of Oncology, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic PathwaysScience, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004